Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
There are three sizes of vein, large, medium, and small. Smaller veins are called venules. The smallest veins are the post-capillary venules. Veins have a similar three-layered structure to arteries. The layers known as tunicae have a concentric arrangement that forms the wall of the vessel. The outer layer, is a thick layer of connective tissue called the tunica externa or adventitia; this layer is absent in the post-capillary venules. The middle layer, consists of bands of smooth muscle and is known as the tunica media. The inner layer, is a thin lining of endothelium known as the tunica intima. The tunica media in the veins is much thinner than that in the arteries as the veins are not subject to the high systolic pressures that the arteries are. There are valves present in many veins that maintain unidirectional flow. Unlike arteries, the precise location of veins varies among individuals. Veins close to the surface of the skin appear blue for a variety of reasons. The factors that contribute to this alteration of color perception are related to the light-scattering properties of the skin and the processing of visual input by the visual cortex, rather than the actual colour of the venous blood which is dark red.
A myocardial infarction is usually clinically classified as an ST-elevation MI (STEMI) or a non-ST elevation MI (NSTEMI). These are based on ST elevation, a portion of a heartbeat graphically recorded on an ECG. STEMIs make up about 25–40% of myocardial infarctions. A more explicit classification system, based on international consensus in 2026, also exists. This classifies myocardial infarctions into three types:
The success of these concerts led to an appearance at the Classic Northwest concert at Safeco Field, opening again for the Eagles. The band took the last leg of their 2017 world tour to Europe, opening for Steely Dan. They toured again with Steely Dan the following year. This tour began in Charlotte, North Carolina and concluded in Bethel, New York. Former Allman Brothers percussionist Marc Quiñones joined the band in May 2018, and the band performed the Toulouse Street and The Captain and Me albums in their entirety along with a selection of hits, at the Beacon Theatre in New York City on November 15–16, 2018. These shows marked their first time at the theatre in 25 years. The concerts were recorded and released as a live album in 2019. During the summer of 2019, the band toured with Santana. Also in 2019, the band performed at the Ryman Auditorium in Nashville and performed the Toulouse Street and The Captain and Me albums in their entirety once again. Michael McDonald joined the band for an encore and they performed "Takin' It to the Streets". At the end of the concert, Simmons announced that McDonald would re-join the band for their 50th Anniversary tour. Since the early 2000s, they have headlined and performed at many benefit concerts including former manager Cohn's B.R. Cohn Winery in Glen Ellen where they had also shared the stage with McDonald in 2006 and 2012. Cohn sold his winery in 2015 to set his primary focus on managing the band and the B.R Cohn Charity Fall Music Festival was relocated to the Sonoma Valley Field of Dreams.
Hydroponics is a type of horticulture and a subset of hydroculture which involves growing plants, usually crops or medicinal plants, without soil, by using water-based mineral nutrient solutions in an artificial environment. Terrestrial or aquatic plants may grow freely with their roots exposed to the nutritious liquid or the roots may be mechanically supported by an inert medium such as perlite, gravel, or other substrates. Despite inert media, roots can cause changes of the rhizosphere pH and root exudates can affect rhizosphere biology and physiological balance of the nutrient solution when secondary metabolites are produced in plants. Transgenic plants grown hydroponically allow the release of pharmaceutical proteins as part of the root exudate into the hydroponic medium. The nutrients used in hydroponic systems can come from many different organic or inorganic sources, including fish excrement, duck manure, purchased chemical fertilizers, or artificial standard or hybrid nutrient solutions. In contrast to field cultivation, plants are commonly grown hydroponically in a greenhouse or contained environment on inert media, adapted to the controlled environment agriculture (CEA) process. Plants commonly grown hydroponically include tomatoes, peppers, cucumbers, strawberries, lettuces, and cannabis, usually for commercial use, as well as Arabidopsis thaliana, which serves as a model organism in plant science and genetics. Hydroponics offers many advantages, notably a decrease in water usage in agriculture. To grow 1 kilogram (2.2 lb) of tomatoes using
Sources: en.wikipedia.org
The lesions occur as multiple cutaneous and subcutaneous nodules up to 4 cm diameter. They may disappear spontaneously, or regress and appear at new sites simultaneously. Topographically lesions may be found on the face, ears, nose, neck, trunk, extremities (including foot pads), perineum and scrotum. Treatment options in SH and CH. SH has proven to be a difficult and frustrating condition to treat. Consequently, many of the early cases were euthanized. Originally we treated dogs with Thymosin (derived from bovine thymus) because of reports of its effectiveness in human LCH cases. Some dogs appeared to respond to this, but not consistently. The original rationale for using thymosin was that SH was likely an immunoregulatory disorder and not cancer. In the majority of instances corticosteroid treatment is ineffective, although in some instances of CH (about 10% of cases), steroid administration is very effective in controlling lesions so steroids are worth trying in this disease given the expense of the alternatives. More recently we have had success with immuno-suppressive doses of Cyclosporin A or Leflunomide. These drugs are potent inhibitors of T cell activation and their ability to abrogate clinical disease gives further support for SH and CH being disorders of immune regulation. Treatment with these drugs is exorbitantly expensive and may be needed for life in dogs with continuously active disease, which usually is the case in advanced SH.
=== Parasitic disease === Ivermectin has been researched in laboratory animals, as a potential treatment for trichinosis and trypanosomiasis. Ivermectin has also been tested on zebrafish infected with Pseudocapillaria tomentosa.
== Exocrine cell type == Morphology is what identifies ductal cells. However, there is barely anything to differentiate pancreatic ductal cells from other bodily ductal cells. There is still a lot unknown about these ductal cells. Their molecular identity still needs to be improved; more knowledge is necessary regarding stage-specific markers and the regulators of ductal cell development. It recently was discovered that the ducts start as separate microlumens in a stratified epithelium that expand, attach, and resolve to form the pancreatic ducts. These cells work with intercalating ducts that link to distinct acini and are within the larger ducts in the two core pancreatic ducts (dorsal and ventral duct) that drain into the intestine. Ductal cells are exocrine, but they are more like endocrine cells when developing. A recent lineage analysis showed that ductal cells came directly from bipotent precursor cells and have the possibility of creating either ductal or endocrine cells. Meanwhile, mature ducts have a restricted ability to transdifferentiate to other types of cells, even when the pancreas is injured.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.